title: [Herpes simplex virus meningitis in 11 patients].
abstract: METHODS
  We reviewed retrospectively the demographic, clinical, biological characteristics and outcomes of 11 patients with HSV meningitis.
  
  
  RESULTS
  Among the 11 patients, six were infected with HIV, four had a documented history of genital herpes, and one recurrent meningitis. In all cases, the onset of symptoms was abrupt, with severe headache and fever. On admission, 9/11 patients had severe meningismus; two patients had HSV anogenital ulcerations. CSF analysis showed in every case a significant increased of leukocytes with a lymphocytic pleocytosis, a mild elevated protein level and a normal glucose level. HSV was detected in the CSF in every case by PCR: the typing performed on six patients was positive in every case for HSV-2. Intravenous acyclovir (IV ACV) was started in 10/11 cases (range: 3-10 days), switched to valaciclovir (VACV) (range: 5-7 days); one patient was treated with ACV per os for 10 days. The total resolution of symptoms occurred within 48hours in every case. Two patients presented with recurrent HSV-2 meningitis in the next two months, with favorable outcome under IV ACV: a switch to long term VACV 500mg/day was prescribed without any recurrence. No patient presented with recurrence after a median follow-up of 30 months.
  
  
  CONCLUSIONS
  Early recognition and treatment might improve the outcome of such infections. Adjunctive oral VACV after IV ACV treatment seems to be associated with a good clinical response in patients presenting with HSV meningitis. The duration of such treatments, including prophylactic treatments to prevent recurrent episodes must be better documented.
authors.affiliation: Département de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, Paris, France.
authors.forename: Charles
authors.initials: C
authors.lastname: Binetruy
authors.forename: Claire
authors.initials: C
authors.lastname: Deback
authors.forename: Claire
authors.initials: C
authors.lastname: Roubaud-Baudron
authors.forename: Henri
authors.initials: H
authors.lastname: Agut
authors.forename: François
authors.initials: F
authors.lastname: Bricaire
authors.forename: Philippe
authors.initials: P
authors.lastname: Bossi
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D004198:Disease Susceptibility; D020803:Encephalitis, Herpes Simplex / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D006558:Herpes Genitalis / Q000453:epidemiology; D018258:Herpesvirus 2, Human / Q000302:isolation & purification; D006786:Hospitals, Urban / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D010297:Paris / Q000453:epidemiology; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir